A Phase 1b Trial of the IRX-2 Regimen, Durvalumab (MEDI4736), and Tremelimumab in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Cyclophosphamide; Indometacin; Omeprazole; Omeprazole
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 05 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Mar 2019.
- 31 Aug 2018 Biomarkers information updated
- 25 Jun 2018 Planned initiation date changed from 1 Jun 2018 to 1 Oct 2018.